<p>Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding. </p>
Joint Statement of Commissioners Mozelle W. Thompson and Pamela Jones Harbour - Victory Memorial Hospital/Provena St. Therese Medical Center
Vector Direct Marketing, LLC, et al.
Advanced Bionutritionals, et al.
RJ Reynolds Tobacco Holdings, Inc. and British American Tobacco p.l.c
Proposed Merger Between RJ Reynolds Tobacco Holdings, Inc. and British American Tobacco p.l.c.
Vega, Esteban Barrios, an individual d/b/a EBV Promotions, Paymentech Promotions, and Promotions of Service
Proposed Acquisition of Horseshoe Gaming Holding Corp., an entity controlled by Jack B. Binion, By Harrah's Entertainment, Inc.
Statement of Commissioner Harbour In the Matter of KFC Corporation
MTS, Inc., et al., In the Matter of
3M Company FKA Minnesota Mining & Manufacturing Company, Petitioner, v. LePage's Inc.orporated, et al.
Hanson Publications, Inc., et al.
Bristol-Myers Squibb Company, In the Matter of
Bristol-Myers Squibb Company (BMS) settled charges that it engaged in illegal business practices to delay the entry of three low price generic pharmaceuticals that would be in direct competition with three of its branded drugs. The complaint alleged that BMS purposely made wrongful listings in the Orange Book of the U.S. Food & Drug Administration and that it also paid a potential competitor over $70 million to delay the entry of its generic drug. The three drugs involved in the complaint are: Taxol (containing the active ingredient paclitaxel) – used to treat ovarian, breast, and lung cancers; Platinol (containing the active ingredient cisplatin) – used for the treatment of various forms of cancer; and BuSpar (containing the active ingredient buspirone) – used to manage anxiety disorders. To prevent recurrence of Bristol's pattern of alleged improper listings, the consent order eliminates Bristol's ability to obtain a 30-month stay on later-listed patents. By denying Bristol the benefit of the 30-month stay on later-listed patents, the order would reduce Bristol's incentive to engage in improper behavior before the PTO and the FDA to obtain and list a patent for the purpose of obtaining an unwarranted automatic 30-month stay.